Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies have been restricted to randomized clinical trials as their only form of testing a treatment; however, due to technological advancement, there are now ways in which data from real-world treatment settings can be collected by clinical researchers. Real-world data is used to support decision making regarding the usage, overall benefits, and risks associated with specific drugs and therapeutic combinations.

In this podcast, David Miklos, BSc, MD, PhD, of Stanford University, Stanford, CA, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, Heinz Ludwig, MD, of the Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Andrea Visentin, MD, PhD, of the University of Padua, Padova, Italy, discuss some of the latest real-world data to have been shared in the fields of lymphoma, myeloma and chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) Congress 2021.

The post EHA 2021: real-world data on myeloma, lymphoma and CLL appeared first on VJHemOnc.